GlassScriptPhysician profile
Shivam Shah
NPI 1144640061
$14,454.75
in general payments reported to CMS, 2019-2025
14 companies · $773 in 2025
The $773 reported for 2025 was more than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.99 · 2021: $113 · 2022: $2,035 · 2023: $4,211 · 2024: $7,222 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,555 · Food and Beverage: $4,251 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,555.02 |
| Food and Beverage | $4,251.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $9,599.52 | 2022-2025 | Indigo System, Ruby Coil, Penumbra System |
| Boston Scientific Corporation | $2,523.76 | 2021-2025 | Spyglass Discover, Therasphere Administration Set, Ekosonic |
| Terumo Medical Corporation | $1,691.41 | 2020-2024 | Glidesheath Slender, Azur Cx Detachable, Hydropearl |
| Sirtex Medical INC | $141.67 | 2023-2024 | Sir-Spheres Microspheres |
| Galvanize Therapeutics, INC | $133.83 | 2025 | Aliya System |
| Medtronic, INC. | $123.20 | 2022-2025 | Kyphon Express II Kyphopak Tray, Hawkone, Concertotm |
| Novartis Pharmaceuticals Corporation | $66.99 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $41.04 | 2023-2024 | Imfinzi, Lynparza |
| Stryker Corporation | $30.55 | 2021 | |
| Celgene Corporation | $25.14 | 2024 | Reblozyl |
| Biohaven Pharmaceutical Holding Company LTD. | $21.91 | 2022 | |
| Sumitomo Pharma America, INC. | $21.90 | 2023 | Aptiom |
| Bard Peripheral Vascular, INC. | $18.34 | 2024 | Venovo |
| Lilly USA, LLC | $15.49 | 2024 | Amyvid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivam Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.